Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Endocrinology
•
Pituitary Disorders
•
General Endocrinology
When do you recommend using L-arginine stimulated copeptin testing to evaluate for central diabetes insipidus (AVP-deficiency)?
Related Questions
What is your approach to differentiating diabetes insipidus from primary polydipsia in the outpatient setting?
Do you recommend the use of GLP1 R agonist therapy in patients with T1DM for weight loss?
Would you consider treating empirically for AVP deficiency in a patient who had pituitary surgery 6 months earlier and complaints of polyuria/polydipsia with dilute urine (without performing water deprivation studies)?
What is your approach to differentiating pseudo-Cushing's state from Cushing's syndrome?
Does growth hormone (GH) replacement therapy reduce the risk of fractures in patients with GH deficiency?
Given the new 2022 WHO classification of pituitary tumors, should we be regularly counseling our patients about the risk of malignancy for what we previously referred to as pituitary adenomas but now classified as pituitary neuroendocrine tumors (PitNETs)?
Should we be using body fat percentage instead of BMI for determining patients' risk of metabolic syndrome?
When do you consider using setmelanotide for treatment of hypothalamic obesity?
When do you recommend the use of oral testosterone replacement over injectable testosterone?
Should we recommend SGLT2i initiation at discharge to all patients hospitalized with acute myocardial infarction?
